BioCentury
ARTICLE | Clinical News

DCF 987: Phase II

August 11, 2003 7:00 AM UTC

BCY completed enrollment in a Canadian Phase II trial of DCF 987. The double-blind, placebo-controlled study is designed to assess the effect of both 500 and 1000 mg twice-daily doses of DCF 987 on pu...